Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-18T07:42:09.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Famotidina: un fármaco suplementario para el tratamiento de la esquizofrenia

Published online by Cambridge University Press:  12 May 2020

P. N. Dannon ,
E. Lepkifker ,
I. Iancu ,
R. Ziv ,
N. Horesh  and
M. Kotler
P. N. Dannon
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
E. Lepkifker
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
I. Iancu
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
R. Ziv
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
N. Horesh
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
M. Kotler
Affiliation:
División de Psiquiatría, Centro Médico de Chaim Sheba, Israel
Get access

Resumen

En un estudio abierto, se añadió famotidina al régimen neuroléptico regular de 11 pacientes esquizofrénicos durante 4 semanas. Se evaluó a cada paciente semanalmente con las escalas SAPS, SANS, CGI y HAM-D-17. Los resultados indican que la famotidina es verdaderamente efectiva como fármaco adjunto para los neurolépticos en el tratamiento de la esquizofrenia.

Keywords

famotidinaantagonistas del receptor H2esquizofrenianeurolépticos
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 8 , November 1997 , pp. 556 - 558
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Carpenter, W, Buchanan, R. Schizophrenia (A Review). N Engl J Med 1994; 330: 681-8.CrossRefGoogle Scholar
Chermos, AN. Pharmacodinamics of famotidine in humans. Am J Med 1986; 84 (suppl 4B): 3-7.CrossRefGoogle Scholar
Deutsch, SI, Rosse, RB, Kendrick, KA, Fay-McCarthy, M et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.. Clin Neuropharmacol 1993; 16: 518-24.CrossRefGoogle ScholarPubMed
Hough, LB. Cellular localization and possible functions for brain histamine: recent progress. Prog Neurob'wl 1988; 30: 469-505.CrossRefGoogle ScholarPubMed
Kaminsky, R, Moriarty, TM, Bodine, J, Wolf, DE, Davidson, M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1989; 335: 1351-2.CrossRefGoogle Scholar
Rifkin, A. Pharmacological strategies in the treatment of schizophrenia. Psych Clin of North America 1993; 16: 351-62.CrossRefGoogle Scholar
Rosse, RB, Kendrick, K, Fay-McCarthy, M, Prell, GD et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.. Clin Neuropharmacol 1996; 19: 341-8.CrossRefGoogle ScholarPubMed
White, JM, Rumbold, GR. Behavioral effects of histamine and its antagonists: a review. Psychopharmacology 1988; 95: 1-4.CrossRefGoogle ScholarPubMed
Yoshimoto, K, Saima, S, Echizen, H, Nakamura, Y et al. Famotidine-associated CNS reactions and plasma and CS drug concentrations in neurosurgical patients with renal failure.. Clin Pharmacol Ther 1994; 55: 693-700.CrossRefGoogle Scholar